Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder

Daniel R. McLeod; Rudolf Hoehn-Saric; Stephen W. Porges; Wesley D. Zimmerli

doi:10.1007/BF02245268

Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder

Daniel R. McLeod, Rudolf Hoehn-Saric, Stephen W. Porges, Wesley D. Zimmerli

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

A noninvasive measure was used to assess the effects of alprazolam, imipramine and placebo on parasympathetic (vagal) cardiac control following 6-weeks of medication in patients with generalized anxiety disorder. Flexible dosage at therapeutic levels resulted in increased heart rate and blood pressure and in decreased cardiac vagal control in patients receiving imipramine but not alprazolam or placebo. About 50% of the variance in heart rate changes and changes in mean arterial blood pressure following treatment with imipramine could be accounted for by changes in cardiac vagal control. Decreased cardiac vagal control can now be added to the list of cardiovascular changes seen following several weeks of treatment with imipramine.

Original language	English (US)
Pages (from-to)	535-540
Number of pages	6
Journal	Psychopharmacology
Volume	107
Issue number	4
DOIs	https://doi.org/10.1007/BF02245268
State	Published - Jun 1992
Externally published	Yes

Keywords

Alprazolam
Blood pressure
Cardiac vagal control
Generalized anxiety disorder
Heart rate
Human subjects
Imipramine
Respiratory sinus arrhythmia

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1007/BF02245268

Cite this

@article{4696a4177a434a6686ec584499a99f23,

title = "Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder",

abstract = "A noninvasive measure was used to assess the effects of alprazolam, imipramine and placebo on parasympathetic (vagal) cardiac control following 6-weeks of medication in patients with generalized anxiety disorder. Flexible dosage at therapeutic levels resulted in increased heart rate and blood pressure and in decreased cardiac vagal control in patients receiving imipramine but not alprazolam or placebo. About 50% of the variance in heart rate changes and changes in mean arterial blood pressure following treatment with imipramine could be accounted for by changes in cardiac vagal control. Decreased cardiac vagal control can now be added to the list of cardiovascular changes seen following several weeks of treatment with imipramine.",

keywords = "Alprazolam, Blood pressure, Cardiac vagal control, Generalized anxiety disorder, Heart rate, Human subjects, Imipramine, Respiratory sinus arrhythmia",

author = "McLeod, {Daniel R.} and Rudolf Hoehn-Saric and Porges, {Stephen W.} and Zimmerli, {Wesley D.}",

year = "1992",

month = jun,

doi = "10.1007/BF02245268",

language = "English (US)",

volume = "107",

pages = "535--540",

journal = "Psychopharmacology",

issn = "0033-3158",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder

AU - McLeod, Daniel R.

AU - Hoehn-Saric, Rudolf

AU - Porges, Stephen W.

AU - Zimmerli, Wesley D.

PY - 1992/6

Y1 - 1992/6

N2 - A noninvasive measure was used to assess the effects of alprazolam, imipramine and placebo on parasympathetic (vagal) cardiac control following 6-weeks of medication in patients with generalized anxiety disorder. Flexible dosage at therapeutic levels resulted in increased heart rate and blood pressure and in decreased cardiac vagal control in patients receiving imipramine but not alprazolam or placebo. About 50% of the variance in heart rate changes and changes in mean arterial blood pressure following treatment with imipramine could be accounted for by changes in cardiac vagal control. Decreased cardiac vagal control can now be added to the list of cardiovascular changes seen following several weeks of treatment with imipramine.

AB - A noninvasive measure was used to assess the effects of alprazolam, imipramine and placebo on parasympathetic (vagal) cardiac control following 6-weeks of medication in patients with generalized anxiety disorder. Flexible dosage at therapeutic levels resulted in increased heart rate and blood pressure and in decreased cardiac vagal control in patients receiving imipramine but not alprazolam or placebo. About 50% of the variance in heart rate changes and changes in mean arterial blood pressure following treatment with imipramine could be accounted for by changes in cardiac vagal control. Decreased cardiac vagal control can now be added to the list of cardiovascular changes seen following several weeks of treatment with imipramine.

KW - Alprazolam

KW - Blood pressure

KW - Cardiac vagal control

KW - Generalized anxiety disorder

KW - Heart rate

KW - Human subjects

KW - Imipramine

KW - Respiratory sinus arrhythmia

UR - http://www.scopus.com/inward/record.url?scp=0026518069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026518069&partnerID=8YFLogxK

U2 - 10.1007/BF02245268

DO - 10.1007/BF02245268

M3 - Article

C2 - 1603897

AN - SCOPUS:0026518069

SN - 0033-3158

VL - 107

SP - 535

EP - 540

JO - Psychopharmacology

JF - Psychopharmacology

IS - 4

ER -

Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this